General
publicado em 17/12/2012 às 15h00:00
   Dê o seu voto:

Research evaluates cost-effective medicines for osteoporosis by age

UFMG study evaluates efficiency of the active ingredients in five age groups of postmenopausal women

 
font size
A-
A+

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.



Foto: MS
Osteoporosis is seen as a public health problem because it is related to high mortality rates and generate a significant volume of spending for SUS
  « Previous
next »  
Osteoporosis is seen as a public health problem because it is related to high mortality rates and generate a significant volume of spending for SUS

Osteoporosis, a disease common in the elderly caused by low bone mineral density, providing fragility fractures, is seen as a public health problem because it is related to high morbidity and mortality and generate a significant volume of spending for the Unified Health System (SUS).

Seeking to know the cost-effectiveness of drugs available for the treatment of osteoporosis in SUS, the researcher Cristina Brandão Streets, Ph.D. in Public Health from the Federal University of Minas Gerais (UFMG), concluded a study that evaluates the effectiveness of the active ingredients in five age groups of postmenopausal women, ranging from 40 to 80 years or more.

According to the author, taking into account the relationship between the number of falls and the onset of therapy, drug treatment is more cost-effective only from the age of 60. Before that, nonpharmacologic preventive measures are recommended, Cristina explains.

In the following two age groups, only two drugs were effective, and for the first age group, 50-59 years, alendronate sodium stood out about the cost-effectiveness, and for the second age group, 60-69 years, only the denosumabe. In both assessments were taken into account the incidence of fractures for each age and therapeutic benefit offered by each drug.

Aged 70 to 79 years and 80 years or more, again, just Alendronate proved cost-effective in the economic evaluation. The alendroanto is available on the UHS clinics, already denosumabe, as a new drug, still needs further studies to evaluate its effectiveness and safety.

According to Cristina, this study points to the need for more awareness for the prevention of disease. It is very important that in addition to drug therapy, there are more activities related to prevention, especially because it is a silent disease that has no symptoms until the onset of fractures, he said.

<b> Prevention </ b>

The author cites a number of initiatives that can prevent the onset of disease and prevent falls that result in fractures. Sun for 10 minutes daily increases the production of vitamin D; intake of calcium-containing foods, particularly dairy products, strengthens bones, avoiding alcohol and tobacco; care for the environment so that it becomes more secure, for example, the installation of hands-runs and supports that assist the elderly in their locomotion and in the case of people over 65 years, making the bone densitometry, lists.

Source: Isaude.net
   Palavras-chave:   Osteoporosis drug    Elderly    Elderly health    UFMG    Federal University of Minas Gerais    SUS    Unified Health System   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: Research evaluates cost-effective medicines for osteoporosis by age
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: Research evaluates cost-effective medicines for osteoporosis by age


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
osteoporosis drug    elderly    elderly health    UFMG    Federal University of Minas Gerais    SUS    Unified Health System   
Comments:
Comment
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.